BRPI0907502A2 - pelo menos um entidade química, composição, e, métodos para tratar um paciente tendo uma condição, para aumentar a função ou atividade do músculo esquelético, para aumentar a eficiência do músculo esquelético, parab aumentar o tempo da fadiga de fibra muscular esquelética rápida, para sensibilizar uma fibra muscular esquelética rápida para produzir força em resposta a baixas concentreações de íons cálcio e para aumentar o tempo de fadiga muscular esquelética - Google Patents
pelo menos um entidade química, composição, e, métodos para tratar um paciente tendo uma condição, para aumentar a função ou atividade do músculo esquelético, para aumentar a eficiência do músculo esquelético, parab aumentar o tempo da fadiga de fibra muscular esquelética rápida, para sensibilizar uma fibra muscular esquelética rápida para produzir força em resposta a baixas concentreações de íons cálcio e para aumentar o tempo de fadiga muscular esqueléticaInfo
- Publication number
- BRPI0907502A2 BRPI0907502A2 BRPI0907502A BRPI0907502A BRPI0907502A2 BR PI0907502 A2 BRPI0907502 A2 BR PI0907502A2 BR PI0907502 A BRPI0907502 A BR PI0907502A BR PI0907502 A BRPI0907502 A BR PI0907502A BR PI0907502 A2 BRPI0907502 A2 BR PI0907502A2
- Authority
- BR
- Brazil
- Prior art keywords
- skeletal muscle
- skeletal
- fatigue
- enhancing
- time
- Prior art date
Links
- 210000002027 skeletal muscle Anatomy 0.000 title abstract 8
- 230000002708 enhancing effect Effects 0.000 title abstract 4
- 210000001087 myotubule Anatomy 0.000 title abstract 4
- 206010049565 Muscle fatigue Diseases 0.000 title abstract 3
- 150000005829 chemical entities Chemical class 0.000 title abstract 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 title abstract 2
- 229910001424 calcium ion Inorganic materials 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title abstract 2
- 230000004220 muscle function Effects 0.000 title abstract 2
- 210000003205 muscle Anatomy 0.000 abstract 2
- 102000007469 Actins Human genes 0.000 abstract 1
- 108010085238 Actins Proteins 0.000 abstract 1
- 206010003694 Atrophy Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 102000003505 Myosin Human genes 0.000 abstract 1
- 108060008487 Myosin Proteins 0.000 abstract 1
- 102000001708 Protein Isoforms Human genes 0.000 abstract 1
- 108010029485 Protein Isoforms Proteins 0.000 abstract 1
- 102000005937 Tropomyosin Human genes 0.000 abstract 1
- 108010030743 Tropomyosin Proteins 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 230000037444 atrophy Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 208000030175 lameness Diseases 0.000 abstract 1
- 208000018360 neuromuscular disease Diseases 0.000 abstract 1
- 210000002235 sarcomere Anatomy 0.000 abstract 1
- 230000001235 sensitizing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2606708P | 2008-02-04 | 2008-02-04 | |
| PCT/US2009/000686 WO2009099594A1 (en) | 2008-02-04 | 2009-02-02 | Certain chemical entities, compositions and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0907502A2 true BRPI0907502A2 (pt) | 2019-01-15 |
Family
ID=40952391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0907502A BRPI0907502A2 (pt) | 2008-02-04 | 2009-02-02 | pelo menos um entidade química, composição, e, métodos para tratar um paciente tendo uma condição, para aumentar a função ou atividade do músculo esquelético, para aumentar a eficiência do músculo esquelético, parab aumentar o tempo da fadiga de fibra muscular esquelética rápida, para sensibilizar uma fibra muscular esquelética rápida para produzir força em resposta a baixas concentreações de íons cálcio e para aumentar o tempo de fadiga muscular esquelética |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7989469B2 (https=) |
| EP (1) | EP2244711A4 (https=) |
| JP (1) | JP2011510985A (https=) |
| KR (1) | KR20100119773A (https=) |
| CN (1) | CN101983061A (https=) |
| AR (1) | AR072242A1 (https=) |
| AU (1) | AU2009210787A1 (https=) |
| BR (1) | BRPI0907502A2 (https=) |
| CA (1) | CA2713864A1 (https=) |
| CL (1) | CL2009000246A1 (https=) |
| CO (1) | CO6290673A2 (https=) |
| EA (1) | EA201001224A1 (https=) |
| EC (2) | ECSP10010430A (https=) |
| IL (1) | IL207367A0 (https=) |
| MX (1) | MX2010008518A (https=) |
| TW (1) | TW200946524A (https=) |
| WO (1) | WO2009099594A1 (https=) |
| ZA (1) | ZA201005780B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8299248B2 (en) | 2006-08-02 | 2012-10-30 | Cytokinetics, Incorporated | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use |
| EP2244711A4 (en) * | 2008-02-04 | 2011-08-24 | Cytokinetics Inc | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS |
| CN102127070A (zh) * | 2010-01-15 | 2011-07-20 | 山东轩竹医药科技有限公司 | 吡啶并环衍生物 |
| EP2730575B1 (en) * | 2011-07-09 | 2015-09-16 | Xuanzhu Pharma Co., Ltd. | Crystal form i of salt of dipeptidyl peptidase-iv inhibitor and preparation method and use thereof |
| KR101951220B1 (ko) | 2011-07-13 | 2019-02-22 | 싸이토키네틱스, 인코포레이티드 | 조합 als 치료법 |
| CN111840294A (zh) * | 2012-04-11 | 2020-10-30 | 赛特凯恩蒂克公司 | 改善对骨骼肌疲劳的抵抗力的方法 |
| HUE057533T2 (hu) | 2014-04-29 | 2022-05-28 | Cytokinetics Inc | Eljárások vitálkapacitás csökkenésének gátlására |
| TWI794369B (zh) * | 2017-12-14 | 2023-03-01 | 丹麥商Ｎｍｄ藥品公司 | 用於治療神經肌肉病症的化合物 |
| TW201927738A (zh) * | 2017-12-14 | 2019-07-16 | 丹麥商Ｎｍｄ藥品公司 | 用於治療神經肌肉病症的化合物 |
| CA3141571A1 (en) | 2019-05-28 | 2020-12-03 | Mankind Pharma Ltd. | 1h-imidazo[4,5-b]pyridin-2(3h)-one compounds and derivatives for inhibition of janus kinase 1 |
| EP4333982A1 (en) * | 2021-05-06 | 2024-03-13 | Exscientia Al Limited | Pkc-theta modulators |
| CN118702622A (zh) * | 2024-08-30 | 2024-09-27 | 阜新达得利化工股份有限公司 | 一种3-溴-2-氰基吡啶的制备方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0206860D0 (en) * | 2002-03-22 | 2002-05-01 | Glaxo Group Ltd | Compounds |
| GB0212048D0 (en) * | 2002-05-24 | 2002-07-03 | Merck Sharp & Dohme | Therapeutic agents |
| US20040166137A1 (en) * | 2002-11-08 | 2004-08-26 | Lackey John William | Hetero-substituted benzimidazole compounds and antiviral uses thereof |
| EP1646614A4 (en) * | 2003-07-01 | 2008-09-10 | Merck & Co Inc | OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA |
| US20050250794A1 (en) * | 2003-12-19 | 2005-11-10 | Andrew Napper | Methods of treating a disorder |
| JP2007529422A (ja) * | 2004-01-29 | 2007-10-25 | エリクシアー ファーマシューティカルズ， インコーポレイテッド | 抗ウイルス治療 |
| WO2005108374A1 (en) | 2004-04-29 | 2005-11-17 | Fmc Corporation | Insecticidal diazole and triazole derivatives |
| GB0420719D0 (en) * | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| EP1959962A2 (en) * | 2005-12-16 | 2008-08-27 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
| US8227603B2 (en) * | 2006-08-01 | 2012-07-24 | Cytokinetics, Inc. | Modulating skeletal muscle |
| ES2558517T3 (es) * | 2006-08-02 | 2016-02-04 | Cytokinetics, Inc. | Ciertas entidades químicas, composiciones y métodos que comprenden imidazopirimidinas |
| CL2007002994A1 (es) * | 2006-10-19 | 2008-02-08 | Wyeth Corp | Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros. |
| ATE543819T1 (de) * | 2006-10-19 | 2012-02-15 | Signal Pharm Llc | Heteroarylverbindungen, zusammensetzungen daraus und behandlungsverfahren damit |
| WO2008075007A1 (en) * | 2006-12-21 | 2008-06-26 | Cancer Research Technology Limited | Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents |
| WO2008121333A1 (en) * | 2007-03-30 | 2008-10-09 | Cytokinetics, Incorporated | Certain chemical entities, compositions and methods |
| EP2244711A4 (en) * | 2008-02-04 | 2011-08-24 | Cytokinetics Inc | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS |
| US7998976B2 (en) * | 2008-02-04 | 2011-08-16 | Cytokinetics, Inc. | Certain chemical entities, compositions and methods |
| CA2744498C (en) | 2008-11-25 | 2017-10-24 | University Of Rochester | Mlk inhibitors and methods of use |
-
2009
- 2009-02-02 EP EP09708594A patent/EP2244711A4/en not_active Withdrawn
- 2009-02-02 CA CA2713864A patent/CA2713864A1/en not_active Abandoned
- 2009-02-02 MX MX2010008518A patent/MX2010008518A/es not_active Application Discontinuation
- 2009-02-02 JP JP2010545031A patent/JP2011510985A/ja not_active Withdrawn
- 2009-02-02 EA EA201001224A patent/EA201001224A1/ru unknown
- 2009-02-02 US US12/364,394 patent/US7989469B2/en not_active Expired - Fee Related
- 2009-02-02 AU AU2009210787A patent/AU2009210787A1/en not_active Abandoned
- 2009-02-02 KR KR1020107018611A patent/KR20100119773A/ko not_active Withdrawn
- 2009-02-02 BR BRPI0907502A patent/BRPI0907502A2/pt not_active Application Discontinuation
- 2009-02-02 CN CN2009801121602A patent/CN101983061A/zh active Pending
- 2009-02-02 WO PCT/US2009/000686 patent/WO2009099594A1/en not_active Ceased
- 2009-02-03 TW TW098103382A patent/TW200946524A/zh unknown
- 2009-02-04 AR ARP090100372A patent/AR072242A1/es unknown
- 2009-02-04 CL CL2009000246A patent/CL2009000246A1/es unknown
-
2010
- 2010-08-02 IL IL207367A patent/IL207367A0/en unknown
- 2010-08-13 ZA ZA2010/05780A patent/ZA201005780B/en unknown
- 2010-08-27 EC EC2010010430A patent/ECSP10010430A/es unknown
- 2010-08-30 EC EC2010010432A patent/ECSP10010432A/es unknown
- 2010-08-30 CO CO10106625A patent/CO6290673A2/es not_active Application Discontinuation
-
2011
- 2011-06-21 US US13/165,281 patent/US20110312975A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20090253737A1 (en) | 2009-10-08 |
| CL2009000246A1 (es) | 2009-06-26 |
| ZA201005780B (en) | 2011-04-28 |
| IL207367A0 (en) | 2010-12-30 |
| WO2009099594A1 (en) | 2009-08-13 |
| MX2010008518A (es) | 2010-11-10 |
| EP2244711A1 (en) | 2010-11-03 |
| EA201001224A1 (ru) | 2011-08-30 |
| JP2011510985A (ja) | 2011-04-07 |
| ECSP10010432A (es) | 2011-01-31 |
| US7989469B2 (en) | 2011-08-02 |
| US20110312975A1 (en) | 2011-12-22 |
| CN101983061A (zh) | 2011-03-02 |
| TW200946524A (en) | 2009-11-16 |
| CO6290673A2 (es) | 2011-06-20 |
| ECSP10010430A (es) | 2011-02-28 |
| KR20100119773A (ko) | 2010-11-10 |
| CA2713864A1 (en) | 2009-08-13 |
| EP2244711A4 (en) | 2011-08-24 |
| AU2009210787A1 (en) | 2009-08-13 |
| AR072242A1 (es) | 2010-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0907502A2 (pt) | pelo menos um entidade química, composição, e, métodos para tratar um paciente tendo uma condição, para aumentar a função ou atividade do músculo esquelético, para aumentar a eficiência do músculo esquelético, parab aumentar o tempo da fadiga de fibra muscular esquelética rápida, para sensibilizar uma fibra muscular esquelética rápida para produzir força em resposta a baixas concentreações de íons cálcio e para aumentar o tempo de fadiga muscular esquelética | |
| AR109995A2 (es) | Método para inhibir la resorción ósea | |
| WO2022026475A3 (en) | Multimeric coronavirus binding molecules and uses thereof | |
| MX374896B (es) | Compuestos con actividad anticáncer. | |
| EA201000559A1 (ru) | Композиции и способы применения антител к склеростину | |
| BRPI0911176B8 (pt) | método de tratar uma composição de célula vermelha sanguínea, composição de célula vermelha sanguínea, e método de reduzir a desidratação em uma composição de célula vermelha sanguínea | |
| MX2010004857A (es) | Compuestos de benzodiazepinona utiles en el tratamiento de afecciones de la piel. | |
| BR112022004587A2 (pt) | Métodos para tratar narcolepsia tipo 1, diminuir eventos tipo cataplexia, aumentar concentração de cálcio intracelular, aumentar latência de sono em manutenção de teste de insônia, melhorar classificação de escaça de sonolência de karolinska, tratar uma doença associada a nível de orexina reduzido, aumentar alerta, melhorar classificação de escala de sonolência epworth, e, composição farmacêutica | |
| DE50204766D1 (de) | Verwendung von kreatin, kreatinin und/oder cyclokreatin zur stärkung und verbesserung der haarstruktur | |
| BRPI0706676B8 (pt) | uso de uma solução aquosa com potencial de oxirredução | |
| BR112012024806A2 (pt) | membro de fixação arcado e implante intervertebral | |
| CY1111161T1 (el) | Χρηση βενζο-συγχωνευμενων ετεροκυκλικων παραγωγων σουλφαμιδιου για τη μειωση των λιπιδιων και τη μειωση των επιπεδων της γλυκοζης στο αιμα | |
| CL2009000309A1 (es) | Derivados fluoroglicosidos aromaticos, composicion farmaceutica que contenga estos compuestos, procedimiento para prepararla y su uso en el tratamiento de la diabetes tipo 1 y 2. | |
| BRPI0801078A2 (pt) | processo para relaxar ou alisar os cabelos | |
| EA201071146A1 (ru) | Способы диагностирования, предупреждения и лечения болезней, связанных с костной массой | |
| BRPI0919489A2 (pt) | composição, kit, métodos de tratamento de uma doença reumática, e de artrite reumatóide em um paciente, agente capaz de ativar células t reguladoras cd4+cd25+ e metotrexato, e, uso de um agente capaz de ativar células t reguladoras cd4+cd25+ e metotrexato | |
| BRPI0612840A8 (pt) | Composição de ração para prevenir ou tratar doença renal, métodos para prevenir ou tratar doença renal e para produzir uma composição de ração, kit, e, meio para comunicar informação ou instruções | |
| ATE499350T1 (de) | Modulatoren der glucocorticoidrezeptor-, ap-1- und/oder nf-kb-aktivität und deren verwendung | |
| Zhao et al. | An embryonic myosin isoform enables stretch activation and cyclical power in Drosophila jump muscle | |
| DE602006006177D1 (de) | Biologisch absorbierbare füllstoffe bestehend aus phospholipidliposomen und hyaluronsäure und/oder derivaten davon | |
| BR112022011364A2 (pt) | Compostos para tratar disautonomia familiar | |
| BR112013013112A2 (pt) | uso de uma composição tendo uma densidade de energia entre 0,9 e 1,5 kcal/ml, composição para uso no controle de níveis de colesterol e triglicérides em um paciente que apresenta diabetes tipo 2 | |
| BRPI0411429A (pt) | tratamento de sintomas associados com vaginose bacteriana | |
| BRPI0506792A (pt) | derivados de furosemida como moduladores de hm74 e seu uso no tratamento de inflamação | |
| ATE487485T1 (de) | Verwendung von d-ribose zur behandlung von vorhofflimmern |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B15I | Others concerning applications: loss of priority |
Free format text: PERDA DA PRIORIDADE US 61/026,067 DE 04/02/2008 REIVINDICADA NO PCT/US2009/000686 DE 02/02/2009 POR NAO CUMPRIMENTO DA EXIGENCIA PUBLICADA NA RPI 2494 DE 23/10/2018 PARA APRESENTACAO DE DOCUMENTO DE CESSAO CORRETO. |
|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |